Literature DB >> 6378494

Comparison of timegadine and naproxen in rheumatoid arthritis. A placebo controlled trial.

H Berry, B Bloom, L Fernandes, M Morris.   

Abstract

A double blind, cross-over design was used to compare the acute effects of timegadine, naproxen and placebo in rheumatoid arthritis. Timegadine appeared to be more effective than naproxen in those variables related to disease activity although there were no statistically significant differences (apart from morning stiffness) where variables were examined individually. There was a tendency to a rise in alkaline phosphatase, and possibly gamma glutamyl transpeptidase, during the 2-week timegadine treatment period. No other biochemical or haematological abnormality was observed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6378494     DOI: 10.1007/bf02041555

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  4 in total

1.  Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis.

Authors:  D M Ritchie; J A Boyle; J M McInnes; M K Jasani; T G Dalakos; P Grieveson; W W Buchanan
Journal:  Q J Med       Date:  1968-07

2.  An unusual profile of activity of a new basic anti-inflammatory drug, timegadine.

Authors:  E Bramm; L Binderup; E Arrigoni-Martelli
Journal:  Agents Actions       Date:  1981-07

3.  A new antiinflammatory compound, timegadine (N-cyclohexyl-N"-4-[2-methylquinolyl]-N'-2-thiazolylguanidine), which inhibits both prostaglandin and 12-hydroxyeicosatetraenoic acid (12-HETE) formation.

Authors:  I Ahnfelt-Rønne; E Arrigoni-Martelli
Journal:  Biochem Pharmacol       Date:  1980-12       Impact factor: 5.858

4.  Basic antiinflammatory compounds. N,N',N''-Trisubstituted guanidines.

Authors:  S Rachlin; E Bramm; I Ahnfelt-Rønne; E Arrigoni-Martelli
Journal:  J Med Chem       Date:  1980-01       Impact factor: 7.446

  4 in total
  3 in total

1.  Comparison timegadine versus naproxen in rheumatoid arthritis.

Authors:  M O'Sullivan; M G Molloy
Journal:  Clin Rheumatol       Date:  1985-09       Impact factor: 2.980

Review 2.  Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

3.  Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses.

Authors:  Catherine Datto; Richard Hellmund; Mohd Kashif Siddiqui
Journal:  Open Access Rheumatol       Date:  2013-02-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.